Novodiag® COVID-19, a fully automated molecular diagnostic test, granted emergency use authorization in Finland for novel coronavirus

  • Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;
  • provides safety for users with a closed system;
  • easy to use with no need for highly trained personnel enabling decentralized testing.

Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received emergency use authorization in Finland for its Novodiag® COVID-19 molecular diagnostic test for the rapid and fully automated detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Continue Reading

Combatting Antimicrobial Resistance – Molecular Diagnostics Holds the Key

Antibiotic resistant bacteria are one of the major threats to the global healthcare system. Some have commented that it is a more immediate threat to us than global warming. A UK independent review estimated that unless effective action is taken, drug-resistant strains of certain bacterial infections will claim 10 million lives each year by 2050. This would be a horrific and tragic loss of life. This unchecked spread of infectious disease was also predicted to result in an economic cost of 100 trillion USD over the next 35 years (1).

Continue Reading